Table 2. Immunohistochemical results of skin and bone marrow (BM) lesions at the times of diagnosis.
| Antigen | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skin | BM (M) |
BM (L) |
Skin | BM (L) |
Skin | BM (M) |
Skin | BM (M) |
Skin | BM (L) |
||||||
| CD4 | + | + | + | + | + | + | + | - | UC | + | + | |||||
| CD56 | + | - | - | + | + | + | + | + | - | + | + | |||||
| CD123 | + | + | + | + | + | + | + | + | + | + | + | |||||
| CD303 (polyclonal) | + | + | + | + | +† | + | + | + | + | + | + | |||||
| CD303 (124B3.13) | - | - | + | + | + | + | + | - | + | - | - | |||||
| CD304 | + | UC | + | + | ND | + | UC | + | UC | - | - | |||||
| TCL1 | - | UC | + | + | +† | - | UC | + | + | + | + | |||||
| CLA | +* | +* | + | + | ND | +* | UC | - | UC | +* | +* | |||||
| CD43 | - | - | - | - | ND | + | - | - | - | + | + | |||||
| TdT | - | - | - | - | - | f+ | + | + | + | - | - | |||||
| CD83 | - | - | - | - | ND | - | - | - | - | - | - | |||||
| TSLP | + | UC | + | + | ND | + | UC | + | UC | + | + | |||||
| TSLP receptor | + | UC | + | + | ND | + | UC | + | UC | + | + | |||||
| Cyclin A index | 35.8±0.6 | UC | 12.4±6.9 | 1.1±0.2 | ND | 37.5±3.8 | UC | 30.6±8.3 | UC | 15.2±2.7 | 6.6±1.8 | |||||
| Cyclin B index | 8.2±0.9 | ND | 4.8±2.7 | 0.5±0.3 | ND | 23.7±4.4 | ND | 11.8±2.4 | ND | ND | ND | |||||
| MIB 1 index | 71.1±4.6 | UC | 66.6±6.9 | 21.0±2.4 | ND | 79.7±2.0 | UC | 71.8±6.0 | UC | 23.6±4.0 | 21.4±4.6 | |||||
M, minimal involvement; L, leukemic; TSLP, thymic stromal lymphopoietin; -, negative; f+, focal positive; +, diffuse positive (less than 30% of neoplastic cells); ND, no data; UC, uncountable due to other hematopoietic cells staining; *, a small-dot paranuclear pattern of positive immunostaining; †, only positive for BM smear.